Boston Scientific accounts are for healthcare professionals only.
Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.
My Boston Scientific account
Access your online applications and manage your customer profile.
Quick Links
Call customer care
The largest prospective, real-world Y-90 study with TheraSphere for the treatment of liver malignancies
(HCC, ICC, mCRC)
All-comers over 5 years
Evaluate effectiveness, safety and patient quality of life (QoL) with TheraSphere treatment in real-world clinical practice, and to identify clinical and dosimetric factors associated with survival
Overall survival (OS) and quality of life (QoL)
Safety, conversion to surgery and factors associated with OS
This study was sponsored by Boston Scientific Corporation. Lead investigators: Etienne Garin, MD and Boris Guiu, MD.
Guiu B, Bailly C, Vibert E et al. Effectiveness and safety of selective internal radiation therapy using yttrium-90 glass microspheres for hepatocellular carcinoma: real-world results from the multi-center prospective PROACTIF cohort of 989 patients. eClinicalMedicine, 2026; 95.
TheraSphere is a registered trademark of Theragenics Corporation used under license by Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation.
